Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Jul 3:14:1168755.
doi: 10.3389/fendo.2023.1168755. eCollection 2023.

Exploring the comparative cardiovascular death benefits of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoring

Samit Ghosal  1 , Binayak Sinha  2
Affiliations
Meta-Analysis

Exploring the comparative cardiovascular death benefits of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoring

Samit Ghosal et al. Front Endocrinol (Lausanne). .

Abstract

Background and aims: Cardiovascular death (CV death) is the most objective component of the primary or secondary endpoint in cardiovascular outcome trials (CVOTs) conducted with sodium-glucose cotransporter 2 inhibitors (SGLT-2is). CV death is often incorporated into primary composite outcomes. It is combined with major adverse cardiovascular events (MACEs) in trials with atherosclerotic cardiovascular disease (ASCVD) at baseline and with hospitalization due to heart failure (hHF) in trials with heart failure at baseline. Unlike the primary composites, CV death reduction by itself demonstrated significant variations among the CVOTs with SGLT-2is. Moreover, the impact of the individual agents within the SGLT-2i group on the reduction in CV death has not been explored objectively. This network meta-analysis was undertaken to construct a hierarchy based on indirect pairwise comparisons and rankings among the individual agents within SGLT-2is.

Methods: A Cochrane library-based web search yielded 13 randomized controlled trials for analysis. Stata/BE 17.0 and RStudio 2022.07.1 Build 554 software were used to conduct a frequentist and Bayesian network meta-analysis. The effect size was assessed based on the risk ratio (RR). Ranking of the individual agents was performed with a frequentist approach (P-score and a multidimensional scaling [MDS] rank system) and a Bayesian ranking (surface under the cumulative ranking [SUCRA]).

Results: Regarding the overall data, SGLT-2is reduced the CV death risk by 12% (RR: 0.88, 95% CI 0.80-0.96). All three scoring methods resulted in empagliflozin scoring the highest. There was a 15% RR reduction in CV death (95% CI 0.71-1.02) in the ASCVD and multiple cardiovascular risk factor (MRF) groups and an 11% RR reduction in the HF group, with empagliflozin ranking the highest in the former group and dapagliflozin in the latter.

Conclusions: Empagliflozin ranked the highest compared to the other SGLT-2is in the overall population and the trials including type 2 diabetes (T2D) patients with ASCVD or MRF at baseline, while dapagliflozin ranked the highest in the trials of patients with HF at baseline.

Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022381556, identifier CRD42022381556.

Keywords: CV death; SGLT-2is; network meta-analysis; ranking; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could appear to influence the work reported in this paper.

Figures

Figure 1
Figure 1
Study selection criteria.
Figure 2
Figure 2
Ranking of different SGLT-2is (Overall data - CV death reduction in the pooled population including ASCVD/MRF & HF): (A). MDS rank score (frequentist), (B). P-score (frequentist), (C). SUCRA (Bayesian).
Figure 3
Figure 3
Ranking of CV death benefit of different SGLT-2is taking ASCVD or MRF as the baseline characteristic: (A). MDS rank score (frequentist), (B). P-score (frequentist), (C). SUCRA (Bayesian).
Figure 4
Figure 4
Ranking of CV death benefit of different SGLT-2is taking HF as the baseline characteristic: (A). MDS rank score (frequentist), (B). P-score (frequentist), (C). SUCRA (Bayesian).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Gao Y, Feng S, Wen Y, Tang T, Wang B, Liu B. Cardiorenal protection of SGLT2 inhibitors–perspectives from metabolic reprogramming. eBioMedicine (2022) 83:104215. doi: 10.1016/j.ebiom.2022.104215 - DOI - PMC - PubMed
    1. Davies M, Aroda V, Collins B, Gabbay R, Green J, Maruthur N, et al. . Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care (2022) 45(11):2753–86. doi: 10.2337/dci22-0034 - DOI - PMC - PubMed
    1. Cosentino C, Grant P, Aboyans V, Bailey C, Ceriello A, Delgado V, et al. . 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European society of cardiology (ESC) and the European association for the study of diabetes (EASD). Eur Heart J (2020) 41(2):255–323. doi: 10.1093/eurheartj/ehz486 - DOI - PubMed
    1. Boer I, Khunti K, Sadusky T, Tuttle K, Neumiller J, Rhee C, et al. . Diabetes management in chronic kidney disease: a consensus report by the American diabetes association (ADA) and kidney disease: improving global outcomes (KDIGO). Diabetes Care (2022) 45(12):3075–90. doi: 10.2337/dci22-0027 - DOI - PMC - PubMed
    1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. . EMPA-REG outcome investigators. empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med (2015) 373:2117–28. doi: 10.1056/nejmoa1504720 - DOI - PubMed

MeSH terms